Purespring Therapeutics Email Format
Biotechnology ResearchEngland, United Kingdom51-200 Employees
Purespring Therapeutics is a London-based biotechnology company focused on kidney diseases, developing gene therapies that directly target podocytes through AAV delivery. Its work draws on the glomerular disease research program led by the University of Bristol, anchoring the company in the field of precision nephrology. Launched in November 2020, the company is developing a program that targets IgA nephropathy by delivering complement factor I to podocytes, with development in a Phase I/II trial. The company has engaged in collaborations with external partners, such as a partnership with Andelyn Biosciences, to support development in nephrology.